Results 101 to 110 of about 73,544 (253)

Deep Brain Stimulation after Subthalamic Focused Ultrasound for Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Ayaka Ichise, Naoki Tani, Yuko Ushida, Takeshi Shimizu, Koichi Hosomi, Satoru Oshino, Keita Kakuda, Kousuke Baba, Manabu Kanemoto, Hideki Mochizuki, Haruhiko Kishima   +10 more
wiley   +1 more source

Striatal Dopaminergic Reserve Shapes the Longitudinal Impact of Peripheral Immune Activation on Motor Progression in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Peripheral immune dysregulation has been implicated in Parkinson's disease (PD) progression, but whether motor deterioration reflects accelerated nigrostriatal degeneration or residual dopaminergic reserve remains unclear. Objectives To examine whether baseline and time‐varying neutrophil‐to‐lymphocyte ratio (NLR) relate to motor ...
Osman Kahveci, Ulaş Ay, Tamer Demiralp
wiley   +1 more source

α‐Synuclein Seeding Discriminates Between LRRK2 G2019S Variant Carriers with and Without Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Reliable biomarkers for Parkinson's disease (PD) pathology detection are essential for research. α‐Synuclein (aSyn) seed amplification assay (SAA) is a validated biomarker for misfolded aSyn. Objective The aim was to assess the association between aSyn SAA and LRRK2‐related PD (LRRK2‐PD) and its link to mitochondrial genetic burden.
Theresa Lüth, Carolin Gabbert, Teresa Kleinz, Christoph Much, Björn‐Hergen Laabs, Sebastian Sendel, Inke R. König, Amke Caliebe, Matthew Farrer, Brian Fiske, Cornelis Blauwendraat, Christine Klein, Joanne Trinh, Global Parkinson's Genetics Program (GP2)   +13 more
wiley   +1 more source

Exploratory SWI-based texture analysis of the substantia nigra on MRI in parkinson's disease. [PDF]

Medicine (Baltimore)
Tavut D, Baykara M, Yildirim H.
europepmc   +1 more source

Targeting the Subthalamic Nucleus in MEGDEL Syndrome: A Case Report of a Clinically Effective Intervention for Debilitating Lingual Dyskinesia and Dystonia

Movement Disorders Clinical Practice, EarlyView.
Philipp Köberle, Florian Lange, Ghadir Abbas, Philipp Capetian, Marius Vogt, Patrick Fricke, Cordula Matthies, Jens Volkmann, Martin Reich, Thomas Musacchio   +9 more
wiley   +1 more source

Cerebellar Network Organization in Parkinson's Disease: Functional Connectivity across Motor and Cognitive Circuits

Movement Disorders, EarlyView.
Abstract Background The cerebellum is increasingly recognized as a key contributor to cognitive reserve and network organization in Parkinson's disease (PD). However, the relationship of cerebello‐cortical and cerebello‐basal ganglia connectivity with cognitive status and nigrostriatal integrity remains incompletely understood.
Chi‐Ying R. Lin, Thamires N.C. Magalhães, Shayla S. Yonce, Ihika Rampalli, Rory Mahabir, Jessica A. Bernard, and the Parkinson's Precision Medicine Initiative   +6 more
wiley   +1 more source

A neuroimaging atlas of the nigrosomes in the substantia nigra based on 3D histology. [PDF]

Sci Data
Brammerloh M, Alkemade A, Bazin PL, Jantzen C, Jäger C, Gasparello A, Zubkov M, Talwar P, Vandewalle G, Herrler A, Pine KJ, Morawski M, Balesar R, Amunts K, Forstmann BU, Weiskopf N, Kirilina E.   +16 more
europepmc   +1 more source

The Gut–Brain Axis in Parkinson's Disease: From Clinical Observation toward Mechanism‐Based Precision Medicine

Movement Disorders, EarlyView.
Abstract Gastrointestinal dysfunction is increasingly recognized as a core feature of Parkinson's disease (PD), affecting quality of life, nutrition, medication response, and potentially the earliest stages of pathogenesis. This perspective traces the evolution of the gut from a neglected source of non‐motor symptoms to a central component of ...
Filip Scheperjans, Per Borghammer, Ronald F. Pfeiffer, Silke Appel‐Cresswell, Ali Keshavarzian   +4 more
wiley   +1 more source

Astrocytes mediate the dopaminergic modulation of tonic GABAergic signaling in substantia nigra. [PDF]

Sci Adv
Simmons DV, Moreno-Ramos OA, Raj DDA, Kaganovsky K, Pamukcu A, Vrieler N, Tkatch T, Xie Z, de Sousa AIS, Zampese E, Ding J, Awatramani R, Wilson CJ, Surmeier DJ.   +13 more
europepmc   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source